财务数据和关键指标变化 - 公司Q2 2024年收入为1480万加元,同比增长11.7%,主要归因于德国收入增加200万加元,以及以色列收入减少40万加元[22][25] - 总销售干花约2,333公斤,平均售价为每克6.09加元,同比增长21%[26] - 成本成本为1390万加元,同比增加46.6%,主要由于收入增加带来的成本增加约280万加元,清理旧原材料约80万加元,以及计提滞销存货约110万加元[27] - 毛利为80万加元,同比下降75.6%,主要由于清理旧存货和计提滞销存货约190万加元[28] - 毛利率为6%,同比下降20个百分点[29] 各条业务线数据和关键指标变化 - 以色列业务方面,公司推出了Flower和Avant两个新的高端品牌,并推出和重新推出了10个新的高端和超高端产品[17] - 公司继续清理滞销的非高端库存,共计清理80万加元,并就滞销存货计提了约110万加元的准备金[18] 各个市场数据和关键指标变化 - 德国市场方面,公司Q2销售额同比增长129%,达到1630万加元,占公司总收入的大部分[12][13][22][25] - 德国市场销售额在Q1至Q2期间增长了200%,显示了大麻合法化对公司业务的巨大影响[12][13] - 公司正在积极调配资源,以支持德国业务的进一步加速增长[15][21] 公司战略和发展方向及行业竞争 - 公司将重点放在德国市场,并正在从以色列建立新的供应渠道来满足德国市场的需求[15] - 在以色列市场,公司将专注于高端和超高端市场,同时采取积极的成本管理措施以支持可持续的盈利能力[16] - 公司原计划与Kadimastem进行反向并购,但最终决定取消该计划,保持公司当前的大麻业务运营[19][20] 管理层对经营环境和未来前景的评论 - 管理层认为德国大麻市场的发展速度超出预期,预计到2025年底市场规模将达到20亿美元[10][11] - 管理层表示,公司将集中资源支持德国业务的加速增长,包括建立合适的团队和稳定的供应链[14][15] - 管理层对公司在德国市场的发展前景持乐观态度,认为公司已做好准备把握这一增长机遇[21] 其他重要信息 - 公司正在评估额外的资本和融资来源,以满足未来的运营需求[37] 问答环节重要的提问和回答 问题1 **Scott Fortune 提问** 提问了公司在德国市场的供应渠道建设情况,包括从以色列进口产品的计划,以及公司在不同细分市场的定位策略[40][41][42][43][44][45] **Oren Shuster 回答** 回答了公司正在采取的措施来增加德国市场的供应,包括从以色列进口产品,以及在德国市场上下游的布局策略[41][42][43][45][48][49] 问题2 **Aaron Grey 提问** 提问了公司在德国市场取得强劲增长的关键因素,以及对毛利率的影响[51][52][53][54][55][56] **Oren Shuster 和 Uri Birenberg 回答** 回答了公司在德国市场的优势所在,包括良好的市场地位和渠道关系,以及对存货管理的影响对毛利率的短期影响,但预计未来几个季度毛利率会有所改善[57][58][59][60]

IM Cannabis Corp. (IMCC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 79.76%. A quarter ago, it was expected that this company would post a loss of $0.96 per share when it actually produced a loss of $0.96, delivering no surprise.Over the last four quarters, the company has surpassed conse ...

TORONTO and GLIL YAM, Israel, Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for ...

TORONTO and GLIL YAM, Israel, July 29, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that on July 26, 2024, it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requireme ...

TORONTO and GLIL YAM, Israel, July 12, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IM Cannabis"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further to its press release dated July 5, 2024, effective today the Company's common shares ("Common Shares") are trading on the Canadian Securities Exchange (the "CSE") and Nasdaq Stock Market LLC ("NASDAQ") on a 6:1 post-consolidated basis (the "Consolidation"). The ...

IMC Germany's accelerated growth potential leans strongly on its supply strategy through its ability to partner with cannabis growers for EU-GMP certification, bolstering the company's supply chain with exclusive product TORONTO and GLIL YAM, Israel, June 5, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is experiencing accelerated growth in Germany after the April 1st partia ...

财务数据和关键指标变化 - 2024年Q1收入为1210万加元,同比下降3%,主要由于汇率影响约20万加元和平均售价下降所致 [15] - 2024年Q1毛利为180万加元,同比下降39%,主要由于清理滞销存货导致成本增加64万加元,以及汇率影响40万加元 [17] - 2024年Q1毛利率为15%,同比下降8个百分点 [17] 各条业务线数据和关键指标变化 - 2024年Q1干花销量约1,873公斤,平均售价为5.68加元/克,同比销量增加1.7%,但平均售价下降13.8% [16] 各个市场数据和关键指标变化 - 德国市场:2023年3月由于大麻合法化的不确定性,药房谨慎采购,导致3月和Q1销售下降;但4月销售已接近过去6个月的两倍 [7] - 以色列市场:2024年Q1公司继续清理滞销存货,降价导致收入和毛利下降;推出8款新高端产品以巩固在高端市场的地位 [9] 公司战略和发展方向及行业竞争 - 公司将重点资源集中在德国市场,因为看好其巨大的增长潜力 [11][13] - 公司已建立EU GMP认证的包装设施,并为加拿大生产商提供第三方审核服务,以确保其获得EU GMP认证,这为公司建立供应链带来优势 [10] - 公司决定不完成收购以色列Oranim药房的剩余股权,将51%的股权转回给原股东 [11][12] 管理层对经营环境和未来前景的评论 - 德国、以色列和美国的监管变化将推动整个大麻行业走向主流 [5][8] - 德国市场需求加速增长,公司已做好供应链准备,有信心把握这一机遇 [7][24] - 以色列新医疗大麻改革将增加患者和处方医生数量,预计将转变以色列医疗大麻市场 [8][9] - 公司已完成2023年的重组,成为一家精干高效的公司,为未来增长做好准备 [13]

IM Cannabis Corp. (IMCC) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.18, delivering a surprise of -12.50%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. IM Cannabis, which belongs to th ...

Exhibit 99.2 IM CANNABIS CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2024 Canadian dollars in thousands (Unaudited) INDEX Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income 4 - 5 Interim Condensed Consolidated Statements of Changes in Equity 6 Interim Condensed Consolidated Statements of Cash Flows 7 - 8 Notes to Interim Condensed Consolidated Financial Statements ...

IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel- Hamas war. TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated. Q1 2024 Financial ...